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Abstract The field of lipidomics focuses upon the non-
targeted analysis of lipid composition, the process of which
follows similar routines to those applied in conventional
metabolic profiling, however lipidomics differs with
respect to the sample preparation steps and chosen ana-
lytical platform applied to the sample analysis. Conven-
tionally, lipidomics has applied analytical techniques such
as direct infusion mass spectrometry and more recently
reverse phase liquid chromatography–mass spectrometry,
for the detection of mono-, di-, and tri-acyl glycerols,
phospholipids, and other complex lipophilic species such
as sterols. The field is rapidly expanding, especially with
respect to the clinical sciences where it is known that
changes of lipid composition, especially phospholipids, are
commonly associated with many disease processes. As a
proof of principle study, a small number of Escherichia
coli isolates were selected on the basis of their sensitivity to
a second generation fluoroquinolone antibiotic, known as
Ciprofloxacin (E. coli isolates 161 and 171, non-ST131
isolates, which are resistant and sensitive respectively:
E. coli isolates 160 and 173, ST131 sequence isolates
which are resistant and susceptible respectively). It has
been proposed that Ciprofloxacin may be a surface active
drug that interacts at the surface-water interface of the
phospholipid bi-layer where the head groups reside. Fur-
ther, antibiotic resistance through intracellular exclusion is
known to result in remodelling of the phospholipid mem-
brane. Therefore, to study the effects of Ciprofloxacin on
both susceptible and resistant bacterial strains, lipid pro-
filing would present an informative approach. Control and
antibiotic challenged cultures for each of the isolates were
compared for changes in metabolite and lipid composition
as detected by FT-IR spectroscopy and RP-UHPLC–MS,
and appraised with a variety of chemometric data analysis
approaches. The developed bacterial lipidomics workflow
was deemed to be highly reproducible (with respect to the
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employed technical and analytical routines) and led to the
detection of a large array of lipid classes as well as high-
lighting a range of significant lipid alterations that differed
in regulation between susceptible and resistant E. coli
isolates.
Keywords Lipidomics  Escherichia coli  Ciprofloxacin
hydrochloride  Antibiotic-resistance  Fourier transform
infrared spectroscopy  Liquid chromatography–mass
spectrometry
1 Introduction
The popularity of metabolomics and the closely related
discipline of lipidomics has risen greatly over the past
decade, across an ever growing range of disciplines and
applications, including, gene function analysis (Fiehn et al.
2000; Roessner et al. 2001), environmental perturbation
(Kaplan et al. 2004; Allwood et al. 2006, 2010), diseases of
clinical significance (Kolak et al. 2007; Mattila et al. 2008;
Oresˇicˇ et al. 2008; Sreekumar et al. 2009; Kenny et al.
2010), and to a large number of organisms including plants
(Lisec et al. 2006; De Vos et al. 2007), fruits, vegetables and
grains (Allwood et al. 2009; Biais et al. 2009; Tikunov et al.
2010), microbes (Koek et al. 2006; Winder et al. 2006, 2008;
Van Der Werf et al. 2008; Lowe et al. 2010), and mammals
(Griffin and Kauppinen 2007; Sreekumar et al. 2009; Kenny
et al. 2010; Velagapudi et al. 2010; Dunn et al. 2007, 2008,
2011). The metabolome and lipidome perhaps represents the
ultimate phenotype of cells, controlled by gene expression
and the modulation of protein function, which in turn are
controlled by the environment and genome mutation (Fiehn
2002; Saito and Matsuda 2010). The field of lipidomics
focuses upon the non-targeted analysis of lipid composition,
the process of data collection and statistical analysis follows
very similar routines to those applied in conventional met-
abolic profiling, however lipidomics differs with respect to
the sample preparation steps and chosen analytical platform
applied to the sample analysis. Conventionally, lipidomics
has applied analytical techniques such as direct infusion
mass spectrometry (DIMS; Goodacre et al. 2002; Han and
Gross 2005; Allwood et al. 2006) and less commonly
reverse phase liquid chromatography–mass spectrometry
(RP-LC–MS; Kolak et al. 2007; Mattila et al. 2008; Wedge
et al. 2011), for the detection of mono-, di-, and tri-acyl
glycerols, phospholipids, and other complex lipophilic spe-
cies such as sterols and ceramides.
Given the influence and importance of microbes upon
many areas of biological, clinical and environmental
research, they are indeed a very significant target for
metabolomics and lipidomics. Many studies have focused
upon the polar central metabolism of microbes (Koek et al.
2006; Winder et al. 2008; MacKenzie et al. 2008),
including applications in several systematic studies to
increase our level of understanding on the control of central
metabolism at the levels of the transcriptome, proteome
and metabolome, with such studies typically focusing upon
model organisms such as Escherichia coli K-12 (Mori
2004) and Saccharomyces cerevisiae (Castrillo et al. 2007;
Herrga˚rd et al. 2008). Further to E. coli being a commonly
employed model species (Mori 2004; Riley et al. 2006), it
is also of great significance as an enteric pathogen (Kaper
et al. 2004), requiring antibiotic treatments in mammals to
clear the gastric infection and alleviate symptoms of gas-
troenteritis. Understanding the actions of antibiotics, which
are frequently poorly described, at the levels of the me-
tabolome and lipidome using model bacteria such as E. coli
is of importance to elucidate the mechanisms of action of
antibiotics in current use and those under development.
Antibiotics are commonly targeted to specific proteins, for
example, fluoroquinolones such as Ciprofloxacin, are tar-
geted to the bacterial DNA topoisomerase II (DNA gyrase)
and DNA topoisomerase IV enzymes which function to
relax supercoiled DNA and perform important processes in
partitioning chromosomal DNA respectively (Greenwood
2000). Therefore, to study the effects of Ciprofloxacin on
the metabolism of bacteria, especially those that are sen-
sitive to the antibiotic, it would be logical to employ an
analytical technique that measures the central metabolome
(Koek et al. 2006; Winder et al. 2008). Such an approach
would be capable of detecting changes in nucleotide
metabolism and how they impact upon other areas of pri-
mary metabolism, potentially revealing direct consequen-
tial effects on metabolism due to the antibiotic mode of
action. However, with the ever growing problem of bac-
terial resistance to antibiotics and the emergence of bac-
teria with resistance to multiple antibiotics (Tomasz 1994;
Wiener et al. 1999; Sa´enz et al. 2004), for example
Methicillin-resistant Staphylococcus aureus (MRSA;
Diederen and Kluytmans 2006), it is perhaps more
important to focus studies on bacterial modes of resistance.
Since bacterial resistance to antibiotics is commonly
dependent on the ability of the bacteria to exclude the
antibiotic from the cell by membrane remodelling via
aminoacylation or cell wall modification by peptidoglycan
cross-linking (RajBhandary and So¨ll 2008; Roy and Ibba
2008), or alternatively by removal of the antibiotic from
the cytoplasm to the extracellular matrix through energy
dependent membrane export (Poole et al. 1993; Okusu
et al. 1996), it may be of great relevance to alternatively
analyse the lipidome of bacteria.
Much research has been previously undertaken on the
optimisation of bacterial growth and metabolic quenching,
as well as the development of suitable GC–MS
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methodologies for the analysis of central metabolism in
E. coli as well as other bacterial species and yeasts (Winder
et al. 2008; MacKenzie et al. 2008). Therefore, the prin-
ciple aim of this investigation was to establish and validate
a method for FT-IR fingerprinting and RP UHPLC–MS
profiling of lipids in antibiotic challenged E. coli, taking
into consideration sample extraction and analysis steps.
FT-IR spectroscopy is a constantly developing analytical
technique often used routinely as a method in bacteriology
being applied to species level identification and discrimi-
nation, as well as a tool to follow phenotypic responses to
abiotic and biotic perturbation (Winder et al. 2006; Preis-
ner et al. 2007; Wehlri et al. 2013). RP LC–MS employing
C18 column chemistries is the standard approach applied to
the analysis of free and membrane lipids in the field of
lipidomics. Therefore both FT-IR and RP UHPLC–MS
were deemed appropriate analytical tools to apply to the
study of changes in lipid quantity and composition in
response to antibiotic challenge in bacteria.
As a proof of principle study, a small number of E. coli
isolates were selected on the basis of their sensitivity to
Ciprofloxacin. The isolates chosen are clinically relevant,
being recently recovered from cases of urinary tract
infection, and included strains from the globally dissemi-
nated ST131 clone (Lau et al., 2008). E. coli isolates 160
and 173, of the ST131 clone, which are classified as
resistant and sensitive respectively, as well as E. coli iso-
lates 161 and 171, non-ST131 strains, which are classified
as resistant and intermediate resistant respectively, were
selected to provide a range of E. coli responses to challenge
with Ciprofloxacin. It has been proposed that Ciprofloxacin
may be a surface active drug that interacts at the surface-
water interface of the phospholipid bi-layer where the head
groups reside (Merino et al. 2003). Further, since antibiotic
resistance through intracellular exclusion is known to result
in remodelling of the phospholipid membrane, the devel-
oped FT-IR fingerprinting and RP-UHPLC–MS lipid pro-
filing approach was deemed to provide an informative
method to study the effects of Ciprofloxacin on both sus-
ceptible and resistant bacterial responses.
2 Materials and methods
2.1 Chemicals
All chemicals used were of analytical reagent or a higher
purity grade. All reference standards were of 99 % mini-
mum purity. All materials were purchased from Sigma-
Aldrich (Gillingham, UK) unless otherwise stated. Cipro-
floxacin hydrochloride was obtained from Discovery fine
chemicals (Dorset, UK), a stock solution was prepared by
dissolving 100 mg in 50 ml of sterile distilled water,
further dilutions were also made with sterile distilled water.
HPLC grade methanol, chloroform and water were pur-
chased from Sigma-Aldrich (Gillingham, UK). Formic acid
(BDH Aristar 1) was purchased from VWR International
(East Grinstead, UK).
2.2 Escherichia coli isolates
Four clinical E. coli isolates were donated by Dr. Mathew
Upton from the Manchester Royal Infirmary. The isolates
were selected on the basis of sequence type and sensitivity
towards quinolones. A sensitive isolate (isolate 173) and a
resistant isolate (isolate 160) of the ST131 clone, as well as
two isolates that were resistant and partially-resistant to
quinolones, isolates 161 and 171 respectively (non-ST131
strains), were selected for the lipidomic analysis.
2.3 Preparation of Escherichia coli cultures, their
antibiotic challenge and determination of minimal
inhibitory concentration (MIC)
Preparation of E. coli inoculates, their culture, challenge
with Ciprofloxacin and determination of MIC are described
in full detail within the Supplementary methods (Sects.
1.1–1.3) and are also presented within Fig. 1. For both the
determination of MIC and also generation of samples for
metabolic fingerprinting and profiling, all cultures were
generated on a single day, with a single batch of culture
media and were incubated in a common orbital shaker. In
the case of larger experiments where sample numbers
demand the generation of cultures in multiple batches
(across days and even weeks), it is recommended that a
minimum of one sample class is maintained within all cul-
ture batches, therefore providing a measure of variance
associated with the different days/batches of culture gener-
ation. Further, by generating inoculums and culture media as
a single lot for all experimental batches, as well as preparing
a single source of both quenching and extraction solvents,
biological and technical variation between the experimental
batches will be minimised. In total 24 cultures were gener-
ated (4 E. coli strains 9 2 treatments (control and antibiotic
challenged) 9 3 biological replicates). The experiment was
designed to test technical (sample quenching) and analytical
reproducibility, with having only a minimal number of
biological replicates generated within a single culture batch,
the experimental design does not permit a measure of the
biological reproducibility of the employed methods.
2.4 Escherichia coli sample collection and quenching
for metabolic fingerprinting and lipid profiling
The sample collection and quenching of metabolism
methods were adapted from the procedures developed by
440 J. W. Allwood et al.
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High throughput screening (HTS)
FT-IR spectroscopic analysis was
carried out using a Bruker Equinox
55 infrared spectrometer (Bruker
Ltd., Coventry, UK). equipped with
an HTX™ module according to the
method of Winder et al. (2006). FT-
IR spectra were recorded directly
from the dried cell biomass in
transmission mode.
Bioscreen Spectrophotometer 
(Labsystems, Basingstoke, UK).
Temperature 37°C, continuous 
medium shake, OD 600 nm, 
measurement interval 10 min.
UHPLC-LTQ-Orbitrap XL MS, m/z 100-1000,
calibrated following manufacturers recommendations
(ESI+ and ESI-). Reverse phase gradient (Hypersil
Gold C18 100 x 2.1mm 1.9 µm particle size: Thermo-
Fisher Ltd.). Gradient programme was adjusted to
run time of 24 min).
8 classes:
ST131 :
160 (control, 0.02 mg/L), 173 (control, 0.02 mg/L)
non-ST131 :
161 (control, 0.3 mg/L), 171 (control, 0.3 mg/L)
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Fig. 1 Schematic of sample generation including (1) bioscreen
analysis to determine the MIC of ciprofloxacin and produce the
growth curves of pathogenic E. coli. (2) FT-IR analysis of samples.
(3) LC–MS analysis of samples after quenching with cold (-48 C)
methanol and extraction with (1:1) methanol:chloroform
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Winder et al. (2008) (Fig. 1), a full description of which is
available in the Supplementary methods Sect. 1.4. All
bacterial cultures were collected on a single day. Due to
limitations in sample handling capacity, quenching was
performed upon randomised batches of six samples at a
time and the procedure requires approximately 20 min per
a batch, therefore the antibiotic treatment of each ran-
domised batch was staggered across 20 min intervals, thus
maintaining that each culture is challenged by the antibi-
otic for precisely 18 h. By quenching the samples across
randomised batches an indication of the procedures tech-
nical reproducibility can be obtained.
2.5 Fourier transform infrared (FT-IR) spectroscopy
High throughput screening (HTS) FT-IR spectroscopic
analysis was carried out using a Bruker Equinox 55
infrared spectrometer (Bruker Ltd., Coventry, UK) equip-
ped with an HTXTM module according to the method of
Winder et al. (2006). Preparation of samples, FT-IR sample
plates and acquisition of spectra are fully described in the
Supplementary methods Sect. 1.5. Each biological sample
was repeat spotted on the FT-IR plate and analysed in
triplicate to provide an indication of analytical variance.
2.6 Sample extraction for UHPLC–MS lipid profiling
The bacterial samples were extracted applying metha-
nol:chloroform (1:1), followed by addition of water so that
polar and non-polar metabolites could be isolated via phase
separation. The method is fully described in the Supple-
mentary methods Sect. 1.6 and was adapted from the
methods described in Winder et al. (2008), which were
originally conceived by Bligh and Dyer (1959). The
extraction method leads to the capture of both free and
membrane lipids within the chloroform phase of the
extract, all of which are amenable to separation and
detection by RP-UHPLC–MS approaches.
2.7 UHPLC–MS analysis
All samples were analysed on the Accela UHPLC system
(Thermo-Fisher Ltd. Hemel Hempsted, UK) coupled to an
electrospray LTQ-Orbitrap XL hybrid mass spectrometry
system (ThermoFisher, Bremen, Germany) adapting the
methods previously described by Wedge et al. (2011) and
provided in full detail in the Supplementary methods Sect. 1.7.
2.8 Processing of raw UHPLC–MS profiles and lipid
identification
The UHPLC–MS raw data profiles were deconvolved using
the freely available XCMS software (http://masspec.
scripps.edu/xcms/xcms.php), the data were quality assured
as described in (Dunn et al. 2008; Wedge et al. 2011) and
normalised by peak sum for each sample (i.e. TIC nor-
malisation). The putative identification of lipid features
was performed applying the PUTMEDID-LCMS set of
workflows (Brown et al. 2011), and a table of the putative
lipid assignments is available in the supplementary infor-
mation (Table S2). Detailed descriptions of deconvolution,
quality assurance and putative lipid identification are pro-
vided in Supplementary methods Sect. 1.8.
2.9 Statistical analyses
Statistical analyses were performed applying the multi-
variate method of principal component-discriminant func-
tion analysis (PC-DFA). PC-DFA scores plots were
employed for data visualisation and loadings plots to
indicate the most significant metabolic features. Further
feature selection was performed on the UHPLC–MS data
for each individual bacterial isolate, comparing the
response between the antibiotic treated and non-treated
controls. First, a multivariate method known as partial least
squares (PLS) regression was applied, this resulted in a
filtered list of the most significant features ordered by the
magnitude of their PLS regression coefficients from largest
to smallest. Secondly, a univariate approach, known as
ANOVA (p \ 0.05), was applied to the significant PLS
regression coefficient lists. Finally, a list of the 50 most
significant features, ordered according to the magnitude of
their PLS regression coefficients (from high to low), which
also had an ANOVA p value of \0.05, was produced for
each bacterial strain. Full descriptions of the statistical
methods are provided in Supplementary methods Sects. 1.9
and 1.10.
3 Results and discussion
3.1 Determination of the Ciprofloxacin minimal
inhibitory concentration (MIC)
So that the lipidomics approach under development did not
lead to the detection of lipid changes associated with the
death of bacterial cells as opposed to detecting lipid altera-
tions that may contribute to the ability of the bacteria to
exclude and remove the antibiotic, thus mediating antibiotic
resistance, it was first necessary to establish the MIC of each
bacterial isolate when cultured in Lysogeny Broth (LB) and
challenged by Ciprofloxacin. Each of the four E. coli clinical
isolates were cultured in LB media and challenged with
Ciprofloxacin solutions ranging from 0.0025 to 100 mg/l in
concentration. Bacterial growth curves were generated by
measuring the OD 600 nm across an 18 h growth period
442 J. W. Allwood et al.
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(Fig. 2). It was determined that the E. coli isolates 161 (non-
ST131) and 160 (ST131), regarded as fully resistant, were
not inhibited in growth even at Ciprofloxacin concentrations
as high as 100 mg/l. For the intermediate-resistant E. coli
isolate 171 (non-ST131) the Ciprofloxacin MIC was deter-
mined to fall between 0.25 and 0.5 mg/l. Whereas for the
sensitive E. coli isolate 173 (ST131) the Ciprofloxacin MIC
was determined to fall between 0.02 and 0.03 mg/l. Based
upon these results, the concentrations of antibiotic were
selected for the challenge of bacteria for sample generation
for metabolic fingerprinting and lipid profiling. For the
E. coli ST131 isolates 160 and 173, in order to permit direct
comparison of metabolic responses, a common antibiotic
concentration of 0.02 mg/l was selected based upon it being
the MIC of the sensitive isolate 173. For the non-ST131
isolates 161 and 171, again in order to permit direct com-
parison of metabolic responses, a common antibiotic con-
centration of 0.3 mg/l was selected based upon it being
intermediate to the MIC of 0.25–0.5 mg/l of isolate 171, and
as being of a great enough concentration to lead to an
inhibitory effect upon growth without resulting in total
bacterial death (Fig. 2).
a b
c d
e
Isolate number Sequence type Quinolone phenotype
MIC range determination 
(mg/L)*
Selected dose to 
challenge the 
bacteria (mg/L)
160 ST131 Fully resistant No effect 0.02
173 ST131 Sensitive 0.03−0.02 0.02
161 non-ST131 Fully resistant No effect 0.3
171 non-ST131 Intermediate resistant 0.5−0.25 0.3
* Ciprofloxacin hydrochloride  highest dose used is 100 mg/L.
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Fig. 2 OD 600 growth curves from 0 to 18 h post antibiotic
challenge to indicate minimal inhibitory concentrations (MIC) of
Ciprofloxacin hydrochloride against Escherichia coli ST131 strains
a 160 (resistant) and b 173 (sensitive) and non-ST131 strains c 161
(resistant) and d 171 (intermediate resistance), e table of predicted
MIC (mg/l Ciprofloxacin)
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3.2 Fourier transform infrared (FT-IR) spectroscopy
based metabolic fingerprinting
FT-IR spectroscopy is an established and constantly
developing analytical technique, which enables the
extremely rapid (seconds per sample), high-throughput
(1,000 s of samples per day) and non-destructive analysis
of a wide-range of sample types (Ellis and Goodacre 2006;
Allwood et al. 2008). FT-IR is also relatively inexpensive
and therefore readily lends itself as a rapid first-round
Fig. 3 FT-IR spectroscopy principle component-discriminant func-
tion analysis (PC-DFA) of 18 h Ciprofloxacin challenged and control
Escherichia coli. a PC-DFA scores plot (DF1 vs. DF2). PC-DFA
loadings plots derived by comparisons of Ciprofloxacin challenged
and control samples for each respective isolate b ST131 strain 160
(resistant), c ST131 strain 173 (sensitive), d non-ST131 strain 161
(resistant), e non-ST131 strain 171 (intermediate resistance). Within
the figures key, C refers to control samples, 0.02 and 0.3 refer to the
antibiotic dose (mg/l), the 95 % confidence Interval (CI) is given in
brackets
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screening method (Allwood et al. 2008) prior to more
expensive and labour intensive approaches. Whilst FT-IR
does not provide high levels of functional information, it
does enable the collection of a holistic fingerprint that can
indicate quantitative changes in peptide, carbohydrate and
lipid levels. Therefore, FT-IR could be employed as a first
round step where comparisons of non-treated and antibiotic
exposed samples are made for numerous bacterial strains
and antibiotic combinations. The FT-IR data would then be
applied to classify the bacterial strains response as resis-
tant, intermediate resistant, or fully susceptible. An
informed selection may then be made to identify which
bacterial strains and antibiotic combinations present the
most interesting metabolic phenotypes to study in more
depth with the lower throughput and financially more
expensive chromatography-MS based approaches. The
FT-IR data may also be consulted in order to select an
appropriate method of chromatography with respect to
analysing changes in lipid or polar metabolite composition.
To visualise the distribution of samples on the basis of
their IR metabolic fingerprints, a PC-DFA scores plot was
generated (Fig. 3a). It was observed that E. coli isolates 160
and 173 (ST131), cluster in close proximity to the negative
side of the DF1 axis. E. coli isolate 161 (non ST131) was
observed to separate from the ST131 isolates largely along
the DF2 axis, which agrees with the results of a previous
FT-IR study (AlRabiah et al. 2013, 2014). Interestingly,
E. coli isolate 171 (non ST131), which is classed as inter-
mediate resistant, was distantly clustered from all of the other
isolates on the positive side of the DF1 axis. The E. coli
isolates classed as fully resistant (isolate 160 and 161),
revealed very little variance between control and Ciproflox-
acin challenged samples, suggesting that on the level of the
metabolic fingerprint, very little metabolic change occurs as a
result of antibiotic challenge. The sensitive E. coli isolate 173
and the intermediate resistant isolate 171 both showed a clear
separation between the control and Ciprofloxacin challenged
sample clusters, with the Ciprofloxacin challenged samples
clustering to the negative side of the DF2 axis.
As a next step, the PC-DFA loadings were derived on the
basis of the wavelengths responsible for the separation of the
control samples from the Ciprofloxacin challenged samples
for each respective E. coli isolate. The fully resistant E. coli
isolates, 160 and 161, despite being of different sequence
type, ST131 and non-ST131 (resulting in their control sam-
ples being clearly clustered from each other in the PC-DFA
scores plot), revealed very similar spectral changes associ-
ated with Ciprofloxacin challenge, suggesting a similar
metabolic shift in the response of the two isolates (Fig. 3b,
d). The most pronounced spectral changes due to Cipro-
floxacin challenge in the fully resistant isolates included
peaks at 1,645 and 1,705 cm-1 corresponding to the amide
spectral region indicating alterations in protein content in
response to Ciprofloxacin challenge. The sensitive E. coli
isolate 173 and the intermediate resistant isolate 171 also
revealed similar spectral changes associated with Cipro-
floxacin challenge (Fig. 3c, e). The most pronounced spec-
tral changes due to Ciprofloxacin challenge in these isolates
included peaks at 1,653 and 1,700 cm-1 again corresponding
to the amide spectral region. Although the preliminary
sample screening approach revealed significant protein
alterations, this is perhaps unsurprising given that Cipro-
floxacin and other fluoroquinolones are predicted to target
enzymatic proteins such as DNA topoisomerase II and IV,
therefore it may be expected that alterations in protein con-
tent would dominate the alterations observed in the lipid,
polysaccharide and mixed spectral regions of the IR spectra.
Given the tight clustering of samples of the same experi-
mental class within the PC-DFA scores plot (Fig. 3a), it was
clear that the within experiment technical reproducibility of
sample growth and collection was high and therefore likely
suited to UHPLC–MS lipid profiling.
3.3 Reverse phase ultra high performance liquid
chromatography–mass spectrometry (UHPLC–MS)
based lipid profiling
Following UHPLC–MS analysis in both ESI positive and
negative ionisation modes, peak deconvolution was per-
formed using the freely available XCMS software (http://
masspec.scripps.edu/xcms/xcms.php) (Dunn et al. 2008;
Wedge et al. 2011), producing a MS Excel based XY
matrix of mass spectral features (with related accurate m/z
and retention time variable pairs) 9 sample, with peak area
inputted where the mass spectral feature was detected in
each sample. In the UHPLC–MS ESI positive mode and
negative mode datasets a total of 2,933 and 1,505 mass
spectral features were deconvolved respectively, features
showing greater than 20 % relative standard deviation
within quality control (QC) samples were removed as were
features detected in the first 0.5 min of LC (void volume),
resulting in a total of 2,642 and 1,317 features in ESI
positive and negative modes respectively.
Following deconvolution, the putative identification of
lipid features was performed applying the PUTMEDID-
LCMS set of workflows (Brown et al., 2011) (Table S2).
An initial appraisal of the putatively identified lipid species
suggested that the phospholipids of E. coli are predomi-
nantly phosphatidyl cholines (PCs) and/or phosphatidyl
ethanolamines (PEs). Given previous reports that state the
major lipid classes of E. coli are represented by PEs,
phosphatidyl glycerols (PGs) and Cardiolipins, with minor
contributions made by phosphatidyl serines (PSs) and
phosphatidic acids (PAs) (Ames 1968), it is perhaps
tempting to speculate that the major lipid species detected
in this study are more likely to be PEs than PCs. The PC
A workflow for bacterial metabolic fingerprinting and lipid profiling 445
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and/or PE phospholipids were largely detected in ESI
positive ionisation mode although a smaller number were
also observed in ESI negative mode. Further, a small
number of PAs were observed in ESI positive and negative
modes and a number of PGs were observed predominantly
in ESI negative mode. Further to phospholipids, a large
number of acylglycerols and free fatty acids were detected,
as well as further diverse lipid species such as sterols,
ceramides and sphingolipids. The putative level of identi-
fication provided by this approach can be categorised as
identification levels 2 and 3 according to the Metabolomics
Standards Initiative guidelines (Sumner et al. 2007).
As a first step towards the appraisal of the UHPLC–MS
datasets, PC-DFA was applied and score plots were gener-
ated (Fig. 4) in order to visualise the distribution of the
various samples and sample groups in relation to each other.
The central positioning of the QC samples through the 0 axes
of both DF1 and DF2 (Fig. 4a, c), indicate that after decon-
volution and quality control steps, the QC samples still
represent an average data point, and that the levels of ana-
lytical and technical reproducibility were high. Similar to
observations within the FT-IR dataset when subjected to
PC-DFA (Fig. 3), the UHPLC–MS datasets also indicated
that alterations due to Ciprofloxacin challenge within the
resistant bacterial isolates (isolates 160 and 161), resulted in
only a small level of sample separation within the PC-DFA
score plots for both ESI positive (Fig. 4a, b) and negative
(Fig. 4c, d) ionisation modes. Perhaps of the greatest signifi-
cance was the clear differentiation between control and Cip-
rofloxacin challenged samples of the sensitive E. coli isolate
173 and the intermediate resistant E. coli isolate 171, with
lipid changes due to Ciprofloxacin challenge being associated
Fig. 4 UHPLC–MS principle component-discriminant function ana-
lysis (PC-DFA) of 18 h Ciprofloxacin challenged and control
Escherichia coli. PC-DFA scores plot (DF1 vs. DF2) of UHPLC–
MS ESI ? mode data a with QCs included and b with QCs removed,
PC-DFA scores plot (DF1 vs. DF2) of UHPLC–MS ESI- mode data
c with QCs included and d with QCs removed. Within the figures key,
C refers to control samples, 0.02 and 0.3 refer to the antibiotic dose
(mg/l), the 95 % confidence interval (CI) is given in brackets
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with a trajectory across the DF1 axis for both ESI positive
(Fig. 4a, b) and negative (Fig. 4c, d) ionisation modes. The
PC-DFA scores plots of the UHPLC–MS datasets overall
indicate that whilst there are alterations in lipid profiles of the
resistant bacterial isolates (isolates 160 and 161) when chal-
lenged by Ciprofloxacin, these are overall minimal in nature
compared to the vast alterations in lipid profiles resulting from
Ciprofloxacin challenge within the sensitive and intermediate
resistant isolates (isolates 173 and 171 respectively).
Following PC-DFA, the next objective was to select which
lipids were significantly altered between control and Cipro-
floxacin challenged samples for each bacterial isolate inde-
pendently, by applying significance testing. Two significance
tests were applied and a consensus drawn between them.
Firstly, a PLS algorithm was applied to the data and the mass
spectral features were sorted by the magnitude of their corre-
sponding PLS coefficient values. Secondly, the ANOVA sta-
tistical test was applied to all mass spectral features. Finally,
starting with the mass spectral feature with the highest PLS
coefficient, the top 50 were selected whose p-value computed
by ANOVA was less than 0.05 (Table S3 and S4). For each
bacterial isolate, the significant features were sorted according
to retention time, since certain lipid species were represented by
multiple mass spectral features, the top 50 list was next reduced
to just the major ion (most intense) observed for each putatively
identified lipid species. The top 50 mass spectral features lists
for each isolate and ESI polarity, after having been reduced in
this manner, were next compiled and a total list of significant
lipid mass spectral features across all bacterial isolates was
obtained. As a next step, trend plots were generated for each of
the significant lipid features, which were then grouped
according to their response to Ciprofloxacin: lipid features that
were commonly up- or down-regulated across both resistant
and sensitive E. coli isolates (Fig. S1); lipid features that were
up- or down-regulated specifically in susceptible or in resistant
isolates (Fig. 5); lipid features that were differentially regulated
between resistant and sensitive isolates (Fig. 6).
3.4 A wide selection of E. coli lipid species are altered
by challenge with Ciprofloxacin, with many
showing differential regulation between sensitive
and resistant E. coli isolates
After the statistically significant lipids had been grouped
according to their response under Ciprofloxacin challenge,
the patterns of response were considered taking into
account the putative assignment of the lipid species and the
levels of saturation within the fatty acid components of the
lipid species, in order to identify potentially significant
trends within the results. Figure S1 reveals a series of lipid
alterations that were grouped as showing common
responses between both resistant and sensitive isolates.
Typically, higher levels of lipid up-regulation were
observed within the sensitive isolate 173 and intermediate
resistant isolate 171, with the lipids being putatively
assigned as PAs, PGs, PAs or PGs, and PGs or DGs (Di-
acyglycerides). Again, for the lipid species that were down-
regulated, typically higher levels of down-regulation were
observed in the sensitive isolate 173 and intermediate
resistant isolate 171, with the lipids being putatively
assigned as PC or PE or PE-NmE (n-Methyl PE) and one
lipid putatively assigned as a highly unsaturated DG with
total chain composition of 40:10 or 38:7 (dependent on the
potential ESI adduct that is formed). The phospholipids
that were generally up-regulated, according to their puta-
tive assignments, had more saturated fatty acids (typically
one or two unsaturated bonds) than the phospholipids that
were down regulated which typically had two-to-four
unsaturated bonds within the fatty acids.
The lipid features that were up- or down-regulated
specifically in susceptible or in resistant isolates are pre-
sented in Fig. 5. The lipids that were significantly up-reg-
ulated in the sensitive isolates generally showed a higher
level of up-regulation within the fully sensitive isolate 173
than the intermediate resistant isolate 171. A total of five
phospholipids assigned as PEs or PCs were up-regulated,
the putative assignments suggest high levels of saturation
within the phospholipid fatty acids, with only one or two
unsaturated bonds being present. The lipids that were sig-
nificantly down-regulated specifically in the sensitive iso-
lates generally showed similar levels of down-regulation
between the fully sensitive isolate 173 and the intermediate
resistant isolate 171. A small number of phospholipids fell
within this response grouping and were putatively assigned
as PCs or PEs and PAs or PSs. A lyso-PC and Cholesteryl-
beta-D-glucoside were also observed to be down-regulated.
Only a small number of lipids were altered specifically
within the resistant isolates 160 and 161, all of which were
highly down-regulated upon challenge with Ciprofloxacin,
these ions were putatively assigned as DGs and PAs.
Perhaps the most interesting series of lipid alterations
observed within the investigation, were those that were
differentially regulated between the sensitive and resistant
isolates (Fig. 6). A large number of phospholipids were
found to be down-regulated in the resistant isolates (iso-
lates 160 and 161) and up-regulated in the sensitive and
intermediate resistant isolates 173 and 171. Most com-
monly the significant lipids were down-regulated in the
bFig. 5 UHPLC–MS trend plots of lipids significantly altered in
response to Ciprofloxacin: Lipids differentially regulated between
susceptible and resistant isolates. a Significantly up-regulated in
susceptible isolates. b Significantly down-regulated in susceptible
isolates. c Significantly down-regulated in resistant isolates. Error
bars represent the standard error within the non averaged data for
each experimental class
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resistant isolates and up-regulated in the sensitive isolate,
with the majority of the significant lipids being putatively
assigned as PCs or PEs and PAs. A small number of DGs
also fell within this response class, with putative assign-
ments suggesting potentially high levels of un-saturation
within the fatty acid components. Interestingly, an ion
putatively assigned as Cholesteryl 11-hydroxy-eicosatet-
raenoate was extremely highly up-regulated, but only
within the intermediate resistant isolate 171, perhaps
indicating an alternative mode of antibiotic exclusion to
that observed within the resistant isolates 160 and 161. In
comparison, only a very small number of lipids were
observed to be up-regulated within the resistant isolates
and down-regulated within the sensitive isolate. One such
ion was putatively assigned as a PG with highly saturated
fatty acids and the other as being either a PA or PG again
with highly saturated fatty acids.
Several trends have emerged within the LC–MS lipi-
domics dataset with the most significant perhaps being that
all phospholipids were assigned as PCs or PEs and PAs or
PGs in class, with their putative assignments suggesting
high levels of saturation within the fatty acids. Alterna-
tively, a large number of ions putatively assigned as DGs
were shown to be significant, many of the putatively
assigned DGs possessed more unsaturated fatty acids than
those observed for the phospholipids. Typically the levels
of up- or down-regulation observed for the sensitive isolate
173 and intermediate resistant isolate 171 were much
higher than the levels of regulation observed within the
resistant isolates, as indicated also by PC-DFA (Fig. 4).
Perhaps of further interest, is that the majority of statisti-
cally significant lipids, were up-regulated in the sensitive
isolate whilst being down-regulated in the resistant isolates,
with only small numbers of significant lipids revealing the
converse trend. It appears that the resistant isolates are
largely characterised by down-regulation of PCs or PEs in
response to Ciprofloxacin challenge, whereas the sensitive
isolates show high levels of up-regulation of PCs or PEs in
response to Ciprofloxacin challenge, perhaps suggesting
that high levels of lipid membrane modulation are taking
place as the antibiotic enters and takes effect upon the
bacterial cell. The developed experimental design has
accounted that the only difference between control and
Ciprofloxacin challenged samples for each respective strain
is the presence of the antibiotic. Therefore it is tempting to
make the assumption that all lipid changes are in direct
response to the effects exerted on the bacterial cell by the
antibiotic. However, previous research has shown that fatty
acid alterations can occur as a response to environmental
changes including temperature, pH, and osmotic pressure, a
phenomena known as phenotypic shift (Crompton et al.
2014). Therefore, with respect to the current study, it must
be considered that whilst some of the observed changes in
lipid composition in response to Ciprofloxacin may be the
result of the antibiotics interaction with the phospholipid
membrane, or in the case of resistant strains, the antibiotics
exclusion via membrane transport, other lipid alterations
may be indirect responses due to the antibiotic altering
environmental conditions such as pH within the bacterial
culture resulting in phenotypic shift.
Given that previous research has suggested that the major
phospholipid species detected in E. coli are PEs (Arnes
1968), it is perhaps unsurprising that the majority of lipids
that were significantly altered by Ciprofloxacin challenge
within this study were putatively assigned as being PEs or
PCs. This may suggest that Ciprofloxacin treatment is spe-
cifically affecting PEs or PCs, or alternatively that these are
the major lipid species of E. coli and thus are more likely to
have changes in their levels detected due to their higher
concentrations and that the alternate species of phospholip-
ids may be close to or under the detection limit of the
employed LC–MS instrumentation. However, if the latter
was the case, then perhaps one would expect to also observe
alterations in the other major lipid classes of E. coli, namely
PGs and Cardiolipins (Arnes 1968). Several previous
investigations, although based upon extracted liposomes
(Bensikaddour et al. 2008) or extracted membrane lipids
(Leying et al. 1986; Merino et al. 2003) of E. coli, rather than
on the bacterial cells within culture as performed in this
study, also suggested that Ciprofloxacin interacts at the
water-phospholipid head group interface of the lipid mem-
brane as revealed by atomic force microscopy (Merino et al.
2003) and also by combination of quasi-elastic light scat-
tering and steady-state fluorescence anisotropy, combined
with attenuated total reflectance (ATR)-FT-IR and 31P NMR
spectroscopy (Bensikaddour et al. 2008), with the studies
suggesting that re-modulation of the phospholipid fatty acids
takes place rather than a conversion of headgroup thus
forming a different class of phospholipid. Taking these
observations into account, it is clearly of much importance
that for the approach applied in this study utilising the high
sensitivity of LC-LTQ Orbitrap MS to investigate lipid
alterations within the ‘‘true’’ bacterial cell to be of greater
value, it will be of massive significance to develop online
LC–MS/MS methods and offline MSn (van der Hooft et al.
2011, 2012; Rojas-Cherto et al. 2012; Roux et al. 2012)
analyses of pre-fractionated samples, in order to not just
unambiguously assign a lipid identification, but also to
identify the levels of saturation and positions of unsaturated
bFig. 6 UHPLC–MS trend plots of lipids significantly altered in
response to Ciprofloxacin: Lipids specifically regulated in susceptible
or resistant isolates. a Up-regulated in susceptible isolates and down
regulated in resistant isolates. b Up-regulated in resistant isolates and
down regulated in susceptible isolates. Error bars represent the
standard error within the non averaged data for each experimental
class
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bonds within fatty acids. Once developed, such methods and
their unrivalled abilities to unambiguously confirm the
identifications of the lipids and elucidate unsaturated fatty
acid bond positions will provide the highest levels of infor-
mation currently possible and will aid greatly our under-
standing of the effects of Ciprofloxacin modulation of fatty
acid structure within the putatively assigned PE and PC
phospholipids.
4 Concluding remarks
The LC–MS workflow developed for the analysis of lipid
species within E. coli when under the challenge of an
antibiotic such as Ciprofloxacin, has been shown to be a
technically and analytically reproducible method that is
useful for discovery phase studies on bacterial modes of
antibiotic resistance. Further, by combining a lipid profil-
ing approach with alternative metabolomics platforms
suited to profiling primary metabolism (e.g. GC–MS:
Winder et al. 2008), the approach may be highly successful
for studying the mechanisms underlying antibiotic modes
of action within sensitive isolates, as well as mechanisms
of resistance. Further, within this study, the developed
workflow has been shown to identify a range of interesting
and potentially clinically significant lipid alterations in
E. coli upon challenge with Ciprofloxacin. However, to
obtain a more satisfactory level of information, the next
step is the development of online RP-UHPLC–MS/MS and
offline direct infusion MSn methods with the LTQ-Orbitrap
XL MS system for identification of lipid species across all
classes. Such an approach will allow identification of
phospholipid classes and fatty acid constituents by
employing orthogonal Retention Time information and
MS/MS spectral fragmentation compared to analytical
standards. By further employing online fraction collection
and performing MS3[5 level experiments employing col-
lision induced dissociation and/or higher energy collision
dissociation methods then the positions of the unsaturated
bond positions within the fatty acid constituents of phos-
pholipids may potentially be identified. The current study
has suggested the great potential of LC–MS lipidomics for
the study of antibiotic modes of action or bacterial modes
of resistance, although greater abilities to unambiguously
identify the lipid species are required to maximise the
biological information content obtained by such a non-
targeted lipidomics approach.
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